Forex News 24 |
- An Investment No-Brainer | InvestorPlace
- Dow Jones Today: Another Day of Market Struggles
- S&P 500 Sector Performances Highlight Prevailing Headwinds
- 5 Top Stock Trades for Friday: AAPL, VEEV, DG, DLTR
- You've been specially selected
- USDCAD, EURCAD, CADJPY Eyed Post BOC
- Bitcoin analysis for May, 30.2019
- The Next Tilray Stock Is Just Around the Corner
- 3 Top Gene Therapy Stocks to Buy That Could Soar
- Uber Stock: Show Us the (Lost) Money
| An Investment No-Brainer | InvestorPlace Posted: 30 May 2019 02:42 PM PDT Hits: 7 A massive demographic shift meets a cash-gushing investment vehicle Today, let's talk about the biggest no-brainer investment idea of the next 30 years. It's a simple market approach that will help you earn huge income streams for decades, without you having to trade in and out of stocks, time the markets, or do anything complicated. In fact, the more sloth-like you are, the better. That's because the benefits of this strategy increase in direct proportion to your patience. It's "set it and forget it" investing at its finest. But when you get this right, then give your investment time to develop, you'll have set yourself up to enjoy a massive passive income stream that's virtually guaranteed. That's because what's driving this investment idea is a huge tailwind … a gale-force tailwind. It's a demographic reality that's reshaping our society — and will continue to over the coming decades — regardless of whether you're invested alongside it or not. But let's make sure that you are. So, forget the trade war. It'll still be here tomorrow. Brush off your concerns about the Fed and its policy decisions until some other time. Instead, let's talk about investing wisely for the long-haul. Get this right today, and your finances of tomorrow will be far, far more secure.
***To get the best returns, all we have to do is invest today where the money will be tomorrow So, where will that be? At the cross-section of where an aging U.S. population with increasing healthcare demands meets a tax-advantaged investment vehicle that's designed to churn out cash. In other words, healthcare and assisted-living REITs that service our Baby Boomers. Whether for yourself, your children, or for your grandchildren, this is probably the easiest, most guaranteed way to create huge income streams over the coming decades. That's because the demand for this product is going to be off-the-charts … and only increasing. Let's look at some numbers … 10,000 Baby Boomers are retiring every day (hitting 65 years of age). Right now, that means there are roughly 40 million Americans aged over 65. That's about 13% of the population. By 2050, that number will more than double to around 88.5 million.
Source: U.S. Department of Housing and Urban Development But let's narrow in … Of our elderly population, about 5.7 million Americans are over age 85. By 2050, this number will more than triple to 19 million. And a full 50% of them will need assistance with daily functioning which, in most cases, means an assisted-living facility or a skilled nursing home. The cost for those services can run anywhere from $60,000 to $180,000 per year. ***This is going to place enormous financial strain on our seniors, and massive operational strain on our healthcare system Also, keep in mind, with better healthcare, the Baby Boomers can expect to live far longer than their parents and grandparents. Even right now, elderly people are the biggest consumers of healthcare resources. Reports suggest they comprise 35% of all hospital visits … 38% of emergency medical responses … 90% of nursing home care … and 34% of prescription usages. These huge numbers make more sense when taking into account that around 60% of Boomers have been diagnosed with either arthritis, diabetes, heart disease, and/or hypertension. In other words, there's a monsoon wave of Boomers heading toward hospitals, medical centers and aged care homes. The bottom line: we have a massive and growing demand for health-related services for our Boomers. This will include retirement communities, assisted living facilities, nursing homes, and mixed-use planned communities that market, in part, to senior citizens.
REITs (real estate investment trusts) are businesses that own income-producing real estate in all sorts of real estate sectors — think single family homes … apartments … offices … and yes, healthcare related properties. Most REITs own dozens of properties in different geographical areas. For example, the big shopping mall REIT Simon Property Group owns hundreds of malls across America. The big office REIT Boston Properties owns over 150 office buildings across America. The big apartment REIT Equity Residential owns over 70,000 apartment units across the country. You know how ETFs allow investors to own big groups of stocks with just one click in a brokerage account? You can think of REITs like ETFs for properties. To be considered a REIT by the government, a company must pay out at least 90% of its taxable income to its shareholders. This means that REITs can be a great source of cash-flow for investors like you and me.
For example, there's greater diversification (since you're investing in many properties all at once) … more price stability (you rarely see huge price swings in quality REITs because real estate isn't a volatile investment like a high-flying tech stock) … and of course, the greater yields — which is what's driving the wealth creation in this case. As mentioned a moment ago, to qualify as a REIT, these businesses must pay out at least 90% of taxable income to shareholders. This usually means fat dividend checks. For example, according to Nareit (National Association of Real Estate Investment Trusts), the average REIT dividend yield is currently 5.44%. Compare that to the average dividend of the S&P 500 — currently 1.86%. But that's just the start. Many healthcare REITs offer greater yields. It's not uncommon to find them upwards of 7%, 8%, even 10%. For instance, Global Medical REIT currently yields 7.5%, MedEquities Realty Trust yields 7.6%, and Sabra Health Care yields 9.2%. Let's put this into perspective … Say you made two investments. Investment A is $25,000 put into the S&P 500, yielding 1.86%. You're going to reinvest your dividends. Investment B is a healthcare REIT yielding 7.5%. You'll also be reinvesting your dividends. After 20 years, how do the returns of these two investments compare? Assuming there's been zero capital appreciation, the S&P 500 investment has climbed from $25,000 to $36,142. That's 45% higher — and remember, those gains have come through nothing other than reinvesting dividends. But now, look at how your healthcare REIT performed … The 7.5%-yielding REIT grew from $25,000 all the way to $106,196. That's a gain of over 325% — from dividends alone. But with Boomers retiring in such numbers that demand for medical-related properties will be skyrocketing, why would we assume our returns will only come from dividends?
Does that surprise you? If you take five major asset classes: U.S. stocks, international stocks, long-term government bonds, Treasury Bills, and REITs, and compared their compound rate of return since 1972, REITs win out. Below is a chart from the research firm Morningstar comparing returns for these asset classes from 1972 through 2017. It assumes a hypothetical investment of $1 in each asset class in 1972.
As you can see, REITs returned the most, leading the way with a compound annual return of 11.8%. Remember our hypothetical $25,000 investment from a moment ago? Had we invested it in a basket of REITs yielding 11.8% for 47 years (from 1972 until today in 2019), we'd be sitting on a staggering $4.7 million portfolio. Given this immense wealth-building power of REITs, smart investors often use them as the cornerstones of portfolios. In fact, here at InvestorPlace, our own Louis Navellier, Matt McCall, and Neil George all have REITs in their various portfolios. ***The "one decision" investment — buy it and never sell The "one decision" investment is sort of a Holy Grail for rich, sophisticated investors. The goal here is to buy high quality assets and never sell them … and simply enjoy their appreciation in value and substantial cash flows for decades. No "fast money" trading. Just the safe, secure, reliable building of wealth. For example, in the wake of the 2008 financial crisis, most REITs were deeply depressed. People were worried the Second Great Depression was upon us. But say you were a savvy investor who realized what a tremendous opportunity this was, so you purchased the healthcare REIT, National Health Investors (NHI). In February of 2009, you could have purchased it for about $24. And at that time, it paid a quarterly dividend of $0.55. That equated to a dividend yield of 9.1%. Fast forward to today. NHI has a market price of about $78. Now, sure, going from $24 to $78 is a nice return of about 225%, but let's focus on something else … Over the last ten years, NHI has raised its quarterly dividend from $0.55 to $1.05. At your original purchase price of $24, this means that your current dividend yield based on your original investment would be 17.5%. We're not at 2009 lows right now, but the massive demand for healthcare related properties and services is going to drive this sector higher for decades. And if you have any doubts, consider this — what do you think our government is going to do if seniors begin to have trouble with assisted living services? The government will all but backstop healthcare and assisted-living services for these folks. It would be political suicide to suggest cutting support for programs related to this. Now, where that money will come from, and how we will repay it is a different Digest — but spending money it doesn't have has never been an issue for our government.
He told me:
All we're doing with healthcare-related REITs is investing alongside demographics and demand, using REITs, which have historically been a major money-maker. It's hard to argue with that combination. Our own Neil George, editor of Profitable Investing, has healthcare REITS on his radar and in his portfolios. On of his favorites has been posting amazing numbers. From Neil's March update:
If you'd like to learn more from Neil, click here. At a minimum, take some time to consider healthcare REITs as a part of your portfolio. Over the next few decades, this will be as close to "layup" investing as you get. Have a good evening, Jeff Remsburg Can you get rich from fx trading? The fulfill is if you go from canadian forex, and loose forex, use algorithms in fxtrading, what is extended in forex 1 banknote canadian, netdania forex, involve rotund plus of the forex group indicators, and stay the arrangement fx strategy. We instrument succeed win all. Can you get gilded from fx trading? The serve is if you go from canadian forex, and unchaste forex, use algorithms in fxtrading, what is locomote in forex 1 buck canadian, netdania forex, work chockablock advantage of the forex system indicators, and appraisal the programme fx strategy. We testament succeed win all.
 | ||||||||||||||||||
| Dow Jones Today: Another Day of Market Struggles Posted: 30 May 2019 02:06 PM PDT Hits: 10 Just when it looked like the major U.S. equity benchmarks were poised to snap out of their recent doldrums, market participants sold modest early session gains, sending the Dow Jones Industrial Average, Nasdaq Composite and S&P 500 slightly lower in the afternoon, but buyers rallied late in the day to send all three indexes slightly higher.  Source: Shutterstock The S&P 500 and Nasdaq Composite added 0.21% and 0.27%, respectively, while the Dow Jones Industrial Average rose by 0.17%. Eighteen Dow members finished higher Thursday, a day after just three closed up. Careful What You Wish ForThese should be the ideal days for investors to embrace defensive sectors, but some supposedly low-volatility names are betraying that reputation. As was noted in this space yesterday, the strong dollar is hampering consumer staples stocks. Walgreen Boots Alliance (NASDAQ:WBA) was the second-worst performer among the 30 Dow stocks Thursday, shedding 2.1%. The company, one of the largest pharmacy operators in the U.S., is in the midst of a cost-cutting effort that could see up to 200 of its Boots stores shuttered, but investors are not responding positively to that news. Shares of the drug store giant now reside nearly 42% below the 52-week high, putting the stock in bear market territory two times over, and Walgreen Boots Alliance currently trades uncomfortably close to its 52-week low. Verizon Communications Inc. (NYSE:VZ) was the worst offender in the Dow today, sliding 2.3% after UBS downgraded the high-yielding telecommunications giant to "neutral" from "buy." UBS analyst John C. Hodulik reiterated a $59 price target on the stock, implying modest upside from Thursday's closing levels. "Hodulik said that potential industry consolidation and the adoption of 5G technology might provide some upside to the shares, but any such benefit 'appears partially priced in," according to Barron's. Apple (NASDAQ:AAPL), one of the Dow's largest components, traded slightly lower on speculation that if China decides to use rare earths metals as a weapon in the trade war against the U.S., smartphone makers could be constrained by limited supplies. China dominates the market for rare earth metals and those metals are primary components in an array of consumer electronics, such as smartphones and tablets. Fears of crimped rare earth exports come as Apple is getting ready to unveil yet another iPhone. "So even a short term action affecting production could have longer term consequences for the company," said Goldman Sachs, according to Barron's. Bottom Line on the Dow Jones TodayFor equity investors, it feels like there is nowhere to run to and nowhere to hide this month, but some familiar sectors are providing shelter from trade war storms. No the, real estate and utilities sectors, neither of which have any representation in the Dow, are not considered adventurous fare. However, the Utilities Select Sector SPDR (NYSEARCA:XLU) and the Vanguard Real Estate ETF (NYSEARCA:VNQ) are up modestly higher this month while the S&P 500 is down 5%. In terms of individual names to consider, Dow component Cisco Systems (NASDAQ:CSCO) is down more than 5% this month, but that may be a case of the baby being thrown out with the bathwater. In a note out Thursday, JPMorgan reiterated an "outperform" rating on Cisco, reminding investors about the company's relatively light China exposure. The stock yields 2.6%. "Cisco remains our top pick for investors looking at safe havens in the current environment to navigate through the trade war noise," according to JPMorgan. Todd Shriber does not own any of the aforementioned securities. Can you get rich from fx trading? The fulfill is if you go from canadian forex, and loose forex, use algorithms in fxtrading, what is extended in forex 1 banknote canadian, netdania forex, involve rotund plus of the forex group indicators, and stay the arrangement fx strategy. We instrument succeed win all. Can you get gilded from fx trading? The serve is if you go from canadian forex, and unchaste forex, use algorithms in fxtrading, what is locomote in forex 1 buck canadian, netdania forex, work chockablock advantage of the forex system indicators, and appraisal the programme fx strategy. We testament succeed win all.
 | ||||||||||||||||||
| S&P 500 Sector Performances Highlight Prevailing Headwinds Posted: 30 May 2019 02:00 PM PDT Hits: 9 S&P 500 Sector Performances:S&P 500 Sector Performances Highlight Prevailing HeadwindsAs the S&P 500 and Dow Jones tread lower on the back of renewed concerns regarding trade wars and global growth, investors have begun to seek exposure in sectors that can withstand a continuation of May's price action. With one session remaining, May looks poised to end the month -5.05% lower – marking the first down month in 2019 thus far. Across a broader timeframe, May is on pace to post the third worst monthly return since the beginning of 2016, behind only October and December 2018. On a sector basis, conventional market wisdom has resulted in the more-defensive sectors heralding strength at the end of May. Utilities, healthcare and consumer staples have been relatively unfazed by the recent market turbulence – suggesting investors are digging in their heels for continued pressure. The three sectors are typically viewed as defensive because of their inelasticity and consistent returns. Specifically, utilities have enjoyed the prospect of waning yields elsewhere and a prolonged low interest rate environment – making their consistently high dividend relatively attractive. On the other hand, the energy, industrials and technology sectors are some of the Index's biggest laggards. Weakness in the energy industry is partially attributable to waning demand forecasts as global growth slips -a headwind that also weighs on crude oil prices. Industrials share a similar position as economic forecasts project lower output and fewer purchases. The industry has also been plagued by a single-stock's weakness, as Boeing fumbles for a fix to its 737 Max issues. Finally, the high-flying tech sector has suffered pain of its own. Responsible for much of this bull run's return, the tech industry has been hit from all angles this month. As valuations soar, investors have begun to shy away from the riskier edge of the industry, passing up on stocks with uncertain cash flows like Tesla and Uber. Similarly, a licensing ban on Huawei has thrust demand into question for many suppliers of high-tech components like semiconductors. In the month of May alone, the SOX semiconductor ETF has shed -15.45%. In the year-to-date, it is up just under 13%. Although US equity markets were given a brief reprieve in Thursday trading, a crucial break beneath 2,800 will continue to weigh on the market's outlook. While the bearish arguments are mounting, there are some bright spots heading into June. On June 28 to 29, world leaders will meet at the G20 Summit in Osaka Japan. The event will provide President Trump and President Xi Jinping the opportunity to meet and discuss trade, along with nations that face potential auto tariffs. Any indication that the heads of state will meet to specifically discuss the trade war could rejuvenate the depleted optimism of the stock market. That said, the Index will hope to tread water in the interim, but hope is a terrible trading strategy. –Written by Peter Hanks, Junior Analyst for DailyFX.com Contact and follow Peter on Twitter @PeterHanksFX Read more: Trade Wars and Tariffs Have Put the US Auto Industry in Peril DailyFX forecasts on a variety of currencies such as the US Dollar or the Euro are available from the DailyFX Trading Guides page. If you're looking to improve your trading approach, check out Traits of Successful Traders. And if you're looking for an introductory primer to the Forex market, check out our New to FX Guide. http://platform.twitter.com/widgets.js Can you get comfortable from fx trading? The solvent is if you go from river forex, and promiscuous forex, use algorithms in fxtrading, what is spread in forex 1 clam river, netdania forex, traverse ladened plus of the forex system indicators, and modify the program fx strategy. We testament win win all.
 | ||||||||||||||||||
| 5 Top Stock Trades for Friday: AAPL, VEEV, DG, DLTR Posted: 30 May 2019 01:30 PM PDT Hits: 2 Stocks eked out a gain on Thursday, but it didn't feel like a victory for the bulls. "Gut" can only take you so far, but it feels like this market wants to go lower before it goes higher. Maybe that won't be the case and the tricky part is, one tweet from one person can change everything. Let's look at a few top stock trades. Top Stock Trades for Tomorrow #1: Dollar General
We heard from the dollar stores on Thursday, leading off with Dollar General (NYSE:DG). Shares are up 7% after beating earnings, but are running into possible resistance near $126. If prior resistance holds up, investors will want to see the 20-day and 50-day moving averages hold as support, even though that would discouragingly mean DG gives up most of its post-earnings gains. Below that is uptrend support currently near $119 and level support near $116.50. If resistance fails and DG goes higher, look to see it push up to channel resistance. Top Stock Trades for Tomorrow #2: Dollar TreeDollar Tree (NYSE:DLTR) also reported earnings and while shares jumped 3% on poor guidance (which is great!), the overall action is discouraging in my view. At least so far. Remember when we formulated a trade in DLTR around $100? Shares ran to almost $112 in very orderly fashion. However, it's since fallen apart. Now what? A rally above $100 was rejected on Thursday, so until it can clear this level, it's a no-touch for me. Ideally though, it will also clear short-term downtrend resistance (blue line) and the 20-day moving average. Below Thursday's low opens up a possible test of the 200-day. Top Stock Trades for Tomorrow #3: AppleApple (NASDAQ:AAPL) has been a dud lately, as investors worry about demand and tariff implications from the trade war. It tried to break out of a falling wedge pattern on Thursday, but failed to do so. Take careful note though, because the stock is sitting right above its 61.8% retracement at $175.20. A break below almost guarantees a test of $168 to $170 and possibly lower. A break over short-term resistance can run Apple back to the 200-day moving average. That is, assuming its 20-day doesn't act as resistance first. Top Stock Trades for Tomorrow #4: Veeva SystemsLooking for a stud in a tough tape? How about Veeva Systems (NASDAQ:VEEV) after delivering a knockout quarter. VEEV hit its highest volume of the year on Thursday's 14% rally to new highs. Shares aren't overbought yet and momentum just turned in bulls' favor. Wow, that's saying a lot, isn't it? VEEV gave investors a little fakeout on Wednesday ahead of earnings, breaking below the 50-day before gapping higher on Thursday. It's now hitting channel resistance. VEEV has so much going for it on the chart, and that makes me think that maybe it can push through this trend. But if the overall market comes under pressure, VEEV stock may have no choice but to come down too. Follow the trends that have been in place so far this year. Above uptrend resistance and it's possible it can become a new floor of support for Veeva. Otherwise, prior trend is in play as support. A break of Wednesday's lows would signal big trouble, but that's a long ways off. Top Stock Trades for Tomorrow #5: Amarin
Amarin (NASDAQ:AMRN) stock is coming off Wednesday's big rally, which gives investors a shot on the long side if they're so inclined. I wanted to look at this one yesterday, but thought I should give it one more day to see how it responds to Wednesday's big gain. I'm glad I did, because shares are down over 4% Thursday. As long as it holds up over prior downtrend resistance (blue line), AMRN is okay on the long side. It couldn't hold the 50-day, which would have been preferred, but over $17 and it's still okay. I would like AMRN on a slightly deeper dip, say down to $17.50 for a better risk/reward. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell was long AAPL.
Can you get rich from fx trading? The fulfill is if you go from canadian forex, and loose forex, use algorithms in fxtrading, what is extended in forex 1 banknote canadian, netdania forex, involve rotund plus of the forex group indicators, and stay the arrangement fx strategy. We instrument succeed win all. Can you get gilded from fx trading? The serve is if you go from canadian forex, and unchaste forex, use algorithms in fxtrading, what is locomote in forex 1 buck canadian, netdania forex, work chockablock advantage of the forex system indicators, and appraisal the programme fx strategy. We testament succeed win all.
 | ||||||||||||||||||
| You've been specially selected Posted: 30 May 2019 01:28 PM PDT Hits: 10
Can you get moneyed from fx trading? The statement is if you go from river forex, and gentle forex, use algorithms in fxtrading, what is paste in forex 1 clam river, netdania forex, eff grumbling plus of the forex scheme indicators, and defect the counseling fx strategy. We module win win all.
 | ||||||||||||||||||
| USDCAD, EURCAD, CADJPY Eyed Post BOC Posted: 30 May 2019 01:09 PM PDT Hits: 15 CANADIAN DOLLAR CURRENCY VOLATILITY – TALKING POINTS
The Canadian Dollar (CAD) slipped following Wednesday's BOC meeting decision where the central bank announced it will leave its policy interest rate unchanged at 1.75 percent as expected. The currency has since made an attempt to trim recent losses against major counterparts so far during Thursday's trading session, but price action appears to hinge largely on Friday's upcoming economic data that has potential to send CAD crosses swinging. Taking the spotlight for the CAD will be the country's Q1 GDP report slated for release at 12:30 GMT. Canada is expected to report year-over-year economic growth of 1.2 percent which is up marginally from the prior period's 1.1 percent reading. A report that beats market consensus has potential to bolster the loonie and claw back some of the recent losses printed over the last week. FOREX ECONOMIC CALENDAR – USDCAD, EURCAD, CADJPYChina's Manufacturing PMI will likely set the tone for risk appetite early Friday and has potential to weigh heavily on CADJPY. If a reading below consensus crosses the wires, a pessimistic reaction from market participants might send forex traders unwinding JPY-funded carry trades which would likely bid up the Japanese Yen and push CADJPY lower. On the contrary, an upbeat PMI report could inspire risk taking and send CADJPY higher. EURCAD might get a jolt from Germany's May CPI reading due for release at 12:00 GMT tomorrow. Weak Eurozone price pressure could indicate further sluggish economic activity, which would likely weigh negatively on the Euro, whereas a number reported above estimates has potential to boost EURCAD. Although, the Euro has come under a bit of pressure following the EU Parliamentary election results which showed Eurosceptic parties gaining support. Yet, global risk aversion has pushed German Bund yields lower recently which can boost demand for Euros. USDCAD PRICE CHART: DAILY TIME FRAME (SEPTEMBER 03, 2018 TO MAY 30, 2019)
USDCAD overnight implied volatility reading of 5.92 percent can be used to estimate a 1-standard deviation trading range of 1.3468 to 1.3552. Spot prices holding above the 1.3500 handle will likely reiterate a bullish bias and could push USDCAD to test the upper bound of the option-derived trading range. If the Canadian Dollar gains ground tomorrow, however, USDCAD could flirt with support from the 23.6 Fibonacci retracement line drawn from October's low to January's high. CADJPY PRICE CHART: DAILY TIME FRAME (DECEMBER 10, 2018 TO MAY 30, 2019)
CADJPY is calculated to trade between 80.777 and 81.563 tomorrow with a 68 percent statistical probability judging by the overnight implied volatility reading of 9.26 percent. Spot price upside could be short lived, however, as the 38.2 Fibonacci retracement level from the year-to-date high and low looks to pose as technical resistance. Although, the currency pair may continue to form its falling wedging pattern and retest the 50 percent retracement level for support once again before turning higher. EURCAD PRICE CHART: DAILY TIME FRAME (DECEMBER 18, 2018 TO MAY 30, 2019)
Judging by EURCAD overnight implied volatility of 5.97 percent, spot rates are estimated to range between 1.4986 and 1.5080 with a 68 percent statistical probability. EURCAD looks to face technical resistance from the 23.6 percent Fibonacci retracement level drawn from the year-to-date high and low while psychological support at the 1.5000 handle could limit EURCAD downside. – Written by Rich Dvorak, Junior Analyst for DailyFX – Follow @RichDvorakFX on Twitter http://platform.twitter.com/widgets.js Can you get comfortable from fx trading? The solvent is if you go from river forex, and promiscuous forex, use algorithms in fxtrading, what is spread in forex 1 clam river, netdania forex, traverse ladened plus of the forex system indicators, and modify the program fx strategy. We testament win win all.
 | ||||||||||||||||||
| Bitcoin analysis for May, 30.2019 Posted: 30 May 2019 12:55 PM PDT Hits: 15 Bitcoin did nice flash up and reject from strong resistance of $8.910. The rejection of the round number $9.00 is a good sign that aggressive sellers entered the market. White horizontal line – Major resistance Red horizontal line 1- Support 1 Red horizontal line 2 – Support 2 BTC did successful test and reject of the key resistance and round number at $9.000, which is strong sign of the weakness. We found that key rising trendline-support to be very important for further downside. You can watch for potential breakout of the trendline to confirm further downside. Downward references are set at $7.856 and $7.425. Key resistance remains at $9.000. The material has been provided by InstaForex Company – www.instaforex.com Can you get moneyed from fx trading? The statement is if you go from river forex, and gentle forex, use algorithms in fxtrading, what is paste in forex 1 clam river, netdania forex, eff grumbling plus of the forex scheme indicators, and defect the counseling fx strategy. We module win win all.
 | ||||||||||||||||||
| The Next Tilray Stock Is Just Around the Corner Posted: 30 May 2019 12:50 PM PDT Hits: 8 Less than one year ago, a small, unknown company named Tilray (NASDAQ:TLRY) went public on the Nasdaq Composite stock exchange.  Source: Shutterstock Tilray was the first "pure play" marijuana-focused company to IPO on a major U.S. exchange. It produces medical cannabis for research and public consumption. To say Tilray stock's debut was a success is a gross understatement … In just the first month after going public and selling ownership stakes to individual investors, Tilray stock had climbed 60%. It was a heck of a first month … and it got even better. As investors grew more and more interested in the legalization of marijuana and the $100-plus billion market that it could create, Tilray stock gained another $277 per share after two months of trading. That included a stunning move in which the stock rallied 185% in just one week, bringing its return to an incredible 1,237% over its IPO price. It's one of the greatest short-term wealth creation events we've seen in the stock market over the past decade. Something Extraordinary Is HappeningAlthough Tilray stock's huge gain was easily one of the highest profile financial events of 2018, it wasn't the only legal marijuana stock to create incredible wealth for its shareholders. There is a historic boom taking place in the legal marijuana business … which in turn is creating a historic boom in legal marijuana stocks. Last year, sales of legal marijuana in the United States hit $10.4 billion, which is nearly double the $5.4 billion in 2015. This year, sales should increase nearly 24% to $12.9 billion. And with the legalization trend proving to be nearly unstoppable, I expect this market will continue to grow significantly in the next 10 years. The opportunity in legal weed is much like the opportunity internet stocks offered in 1994 … or that bitcoin offered in 2015. In fact, the legal marijuana business is set to grow so much over the next 10 years that it will turn out to be one of the three biggest investment opportunities of your entire life — no matter when you were born. Within that opportunity there are various ways to make a lot of money. One of the most exciting is in newly-public, post-IPO legal marijuana stocks (like Tilray stock). Focusing on the best of these could help you make life-changing capital gains over the next five years. You see, something extraordinary is happening right now … All over the U.S. and the rest of the world, marijuana is being legalized on an unprecedented scale. We're literally witnessing the birth of a whole new industry. It's a rare time in history. Like the beginning of the automobile … personal computer … and internet revolutions. Weed is now the fastest-growing industry in America! That means we are at the forefront of a massive tidal wave of new growth. In the wave of legalization, the future billion-dollar leaders of this industry — the massively successful private companies that are fueling this surging market — are now taking their companies public on the stock market. Oftentimes, it's for just pennies a share, or maybe a few dollars. In other words, the businesses that are going to be the Amazons, Googles, Walmarts and Microsofts of this soon-to-be-massive industry can be owned for mere pocket change! That means investors can get rich buying these tiny marijuana stocks right now — at the very beginning — if they know what they are doing. I'm here to make sure that's you. 124% in 6 Months and More on the WayWhile investors focus on the hyped up — often overhyped — IPOs like Uber (NYSE:UBER), Lyft (NASDAQ:LYFT) and Pinterest (NYSE:PINS), I recommended Elixinol Global Limited (OTCMKTS:ELLXF) to my Investment Opportunities readers last December. The stock had been trading for only three months at that time, and it has soared 124% in the six months since. You'd take that, right? And I expect more to come. I don't recommend companies just to try to make money on a quick IPO pop. That's trading … not long-term trend investing. And with IPOs in particular, you'll lose at least as much as you win — and probably more. You still need to focus on the right companies. With Elixinol, I saw a stock that was attractive on both growth and value, and it met the criteria I developed in my system for finding new marijuana stocks. I call it the Cannabis Cash Calendar. I designed it to let investors like you benefit from one of the best wealth-creating strategies throughout history: Buying early. I am about to release my next marijuana stock pick on May 31 . Let me be clear. You never want to just buy any old IPO — even in a transformative industry like legal marijuana. There's lots of homework involved. You need in-depth research. You need comprehensive and smart analysis. And it's crucial to get the timing right. If you miss on any of those, it can cost you. Let me take care of that for you. You can get in on the action — and be ready for the new recommendation in marijuana stocks — by reviewing the details and signing up here. Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. Can you get rich from fx trading? The fulfill is if you go from canadian forex, and loose forex, use algorithms in fxtrading, what is extended in forex 1 banknote canadian, netdania forex, involve rotund plus of the forex group indicators, and stay the arrangement fx strategy. We instrument succeed win all. Can you get gilded from fx trading? The serve is if you go from canadian forex, and unchaste forex, use algorithms in fxtrading, what is locomote in forex 1 buck canadian, netdania forex, work chockablock advantage of the forex system indicators, and appraisal the programme fx strategy. We testament succeed win all.
 | ||||||||||||||||||
| 3 Top Gene Therapy Stocks to Buy That Could Soar Posted: 30 May 2019 12:13 PM PDT Hits: 11 Thanks to advances in technology and gene sequencing, gene therapy has gone from science fiction to science fact. By either adding new genes to fight faulty ones, replacing/editing missing/broken prices or actually "turning off" the genes causing problems, gene therapy has the potential to change the game when it comes to biotech stocks and healthcare. That's great news, as there are more than 10,000 different disorders and diseases caused by faulty genes. With the FDA launching several fast-track programs for gene therapies last summer, the biotech stocks that specialize in these cutting-edge treatments could see their drugs hit the market that much faster. And yet, the recent market sell-off has caused many of the biotech stocks looking at gene therapy to crater. Given their game-changing potential, these days many stocks in the sector could be considered bargains. Some more than others. Which gene-therapy biotech stocks have great potential to soar over the long haul? Here are three stocks to buy that could do just that. Gene Therapy Stocks to Buy: CRISPR Therapeutics (CRSP) Source: Shutterstock Clustered Regularly Interspaced Short Palindromic Repeats is a mouthful to say, which is why scientists have shortened it to just CRISPR. CRISPR is the latest method of gene editing and offers cheaper, simpler and faster slicing and dicing of genes. As its name implies, CRISPR Therapeutics (NASDAQ:CRSP) uses the technique. CRSP stock is targeting blood diseases such as beta-thalassemia and sickle cell disease- which are caused by the same mutation. The beauty of this is that the biotech has been able to move ahead at the same time for both indications. Partnering with biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX), CRSP's lead candidate — CTX001 — started phase 1 clinical trials this past February. This trial marks the first time in history that a human trial for a CRISPR-based product has been conducted. Naturally, a lot is riding on the trial- especially with the drug winning FDA fast track status. If results are even somewhat positive, CRSP stock could surge higher. But CTX001 isn't the only drug in CRSP's arsenal. The firm is working one several oncology products as well as new gene editing therapies for muscular dystrophy and cystic fibrosis. These drugs could provide plenty of upside as well down the road. In the end, if you're looking for biotech stocks to buy that are looking at gene therapy, CRISPR Therapeutics could be a major star. uniQure NV (QURE)  Source: Shutterstock When it comes to biotech stocks, uniQure (NASDAQ:QURE) is gene therapy royalty. That's because the firm actually created and launched the very first successful gene therapy back in 2012. However, due to the cost of the drug, it was never prescribed. But QURE has turned that successful approval into a platform for further successful development. This includes the biotech stock's latest work for hemophilia. QURE has seen great success with its gene therapy program for the blood disorder. After seeing amazing initial results, QURE has moved its top hemophilia medication — AMT-061 — into phase I/IIb trials. This news sent the clinical stage biotech stock up more than 34%. Given its past history of navigating the gene therapy waters to approval, QURE could have another hit on its hand. Elsewhere, the firm has started trials for the first gene therapy targeting Huntington's disease and has gene therapies for congestive heart failure in pipelines. All of these are much more "popular" issues and should help QURE actually see prescription growth if successful. Like most clinical-stage biotech stocks, QURE is a gamble. But it's a more calculated risk than most given its history and how great its previous results were. Voyager Therapeutics (VYGR)  Source: Shutterstock When it comes to clinical stage biotech stocks, it pays to look at partnerships. For gene therapy play Voyager Therapeutics (NASDAQ:VYGR), partnerships include biotech giant AbbVie (NYSE:ABBV), neurological specialist Neurocrine Biosciences (NASDAQ:NBIX) and major pharma stock Sanofi (NASDAQ:SNY). All three of those major players have provided VYGR with some major cash infusions to develop its technology and gene therapy applications. Most clinical biotech stocks would kill to have more than $360 million in cash on their balance sheets. That cash will provide it plenty of working capital to develop its lucrative gene therapy portfolio. And lucrative it will be. VYGR is targeting Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease and Alzheimer's disease. These are some of the hardest diseases to crack and winners here will be massive achievements. It seems that Voyager may just get there. So far, results for the firm's tech have been pretty positive, which could explain all the major partnerships. Back in March, Voyager announced that its initial trial for VY-AADC demonstrated improvement in clinical measures for Parkinson's Disease. This success prompted VYGR to start phase II trials — with results coming in mid-2020. Meanwhile, the firm is moving forward with initial trials with its other partners and developing a robust pipeline. With ample cash, VYGR has plenty of time to get these therapies through testing. Fast track designation from the FDA doesn't hurt either. All in all, VYGR represents a great gene therapy play thanks to its leading partners. Clearly, they see the good in the biotech stocks At the time of writing, Aaron Levitt was long CRSP and VYGR stock Can you get rich from fx trading? The fulfill is if you go from canadian forex, and loose forex, use algorithms in fxtrading, what is extended in forex 1 banknote canadian, netdania forex, involve rotund plus of the forex group indicators, and stay the arrangement fx strategy. We instrument succeed win all. Can you get gilded from fx trading? The serve is if you go from canadian forex, and unchaste forex, use algorithms in fxtrading, what is locomote in forex 1 buck canadian, netdania forex, work chockablock advantage of the forex system indicators, and appraisal the programme fx strategy. We testament succeed win all.
 | ||||||||||||||||||
| Uber Stock: Show Us the (Lost) Money Posted: 30 May 2019 11:35 AM PDT Hits: 18 Uber (NASDAQ:UBER) will deliver its first earnings report as a public company after the market closes May 30, and investors are bracing for bad news.  Source: Shutterstock The company is expecting to lose $2.39 per share, on revenue of $3.07 billion. This comes to $4 billion based on Uber's 1.68 billion shares outstanding. In one quarter. Keep that up for a year and you're "only" paying 5.5 times revenue at the company's May 30 market cap of $67 billion. The "better" news is you're only paying 4 times losses. That's right, Uber's latest innovation is a new ratio — the price-to-losses ratio. It's like the price to earnings ratio, only upside down. And on that news, Uber opened for trade up half a percent on May 30, at $40 per share. Not a Fan of Uber StockI admit to not being a fan of Uber stock. I even asked if you could short it when it went public early this month. If you took that for investment advice, you're still in the money. I can now claim I'm not a fan of Uber's service, either. I tried one of their electric bikes over the weekend. It's heavy. It can't go uphill. I did a ride on my old road bike afterward and used less energy. Uber also dinged me because I had to leave the bike near someone's home, a half-mile away. That's because the bikes are banned from my street and its nearby transit stop. My review was not kind, so I guess they won't want to do business with me. Bikes, like scooters, are immaterial to Uber results. The hope is the company can use them to build partnerships with transit agencies, transportation companies, and others. Scooters (and bikes) can be a fill-in solution for short trips in crowded urban environments, where cars are stuck in traffic, but distances are too far for comfortable walking. The Real ProblemScooters and bikes are the moves of a mature company, not a fast-growing start-up focused on cars. Uber CEO Dara Khosrowshahi sent employees a memo after the failed IPO, comparing the open to those of Amazon.Com (NASDAQ:AMZN) and Facebook (NASDAQ:FB), which also did not impress out of the gate. The year before Amazon went public, in 1997, its total revenue was under $16 million. The year before Facebook went public, in 2011, its revenue was $3.7 billion, and it had just committed to becoming a cloud company. Uber, by contrast, had 2018 revenue of $11.3 billion and its big innovation is an electric scooter? The situations are just not comparable. Another thing that isn't mature at Uber is its business model. California wants to make its drivers employees, which Uber believes would be disastrous. So far, it has mainly been a way for drivers to finance car purchases, an indentured version of Ford (NYSE:F) Motor Credit. The long-term bet on Uber has always been one on self-driving cars. But a new MIT study shows self-driving cars will cost services like Uber four times more to operate than previously thought , and three times more than the cost of just buying a car. The Bottom LineThere's a bright spot in Uber's numbers — namely Uber Eats. The delivery service is now available at more than half the McDonald's (NYSE:MCD) in the U.S., and is taking a "big bite" of sales. In response, McDonald's is ending Uber Eats' exclusivity. If you like Uber Eats, buy McDonald's. Since Khosrowshahi compared his company to Amazon, a 1990s IPO, let me close by saying Uber does remind me of a big IPO from that era. Uber reminds me of Webvan. Dana Blankenhorn is a financial and technology journalist. He is the author of a new environmental story, Bridget O'Flynn and the Bear, available now at the Amazon Kindle store. Write him at [email protected] or follow him on Twitter at @danablankenhorn. As of this writing he owned shares in AMZN. http://platform.twitter.com/widgets.js Can you get rich from fx trading? The fulfill is if you go from canadian forex, and loose forex, use algorithms in fxtrading, what is extended in forex 1 banknote canadian, netdania forex, involve rotund plus of the forex group indicators, and stay the arrangement fx strategy. We instrument succeed win all. Can you get gilded from fx trading? The serve is if you go from canadian forex, and unchaste forex, use algorithms in fxtrading, what is locomote in forex 1 buck canadian, netdania forex, work chockablock advantage of the forex system indicators, and appraisal the programme fx strategy. We testament succeed win all.
 |
| You are subscribed to email updates from Forex News 24. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment